Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments
I want to filter the trials based on location, phase of development, or drug name, category or target
No preference
PARP
No preference

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT02693535IIOvarian expansion for CDKN2A loss or MUT, or high TMB, or ERBB2/ERBB3 AMP, MUT or over-expression or Advanced solid tumors with molecular alterations in ALK, ATM, BRAF, BRAFV600E/D/K/R, BRCA1/2, CDK4, CDK6, CDKN2A, CSF1R, KIT, MET, MLH1, MSH2, MSH6, mTOR, PALB2, PDGFR, PDGFRB, PMS2, POLD1, POLE, RAF-1, RET, ROS1, TSC1/2, VEGFR, high MSI, high TMBTargeted Agent and Profiling Utilization Registry (TAPUR) StudyAL, AZ, CA, FL, GA, HI, IL, IN, ME, MI, NE, NH, NC, ND, OK, OR, PA, SD, TX, UT, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AbemaciclibBemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, VerzenioCDK4/6 inhibitorApproved in Other Cancers
AfatinibBIBW 2992 MA2, Gilotrif, Afatinib dimaleateEGFR, HER2, HER4 kinase inhibitorApproved in Other Cancers
CobimetinibXL518, GDC-0973, CotellicMEK1 inhibitorApproved in Other Cancers
Crizotinibc-met/HGFR tyrosine kinase inhibitor PF-02341066, PF-02341066, Xalkoric-Met and ALK kinase inhibitorApproved in Other Cancers
IpilimumabAnti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, YervoyBlocks CTLA-4 inhibition of T cellsApproved in Other Cancers
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
PalbociclibPD-0332991, PD0332991, IbranceCDK4/6 inhibitorApproved in Other Cancers
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
PertuzumabPerjeta, monoclonal antibody 2C4, rhuMAb2C4HER2 dimerization inhibitorApproved in Other Cancers
RegorafanibBAY73-4506, multikinase inhibitor BAY 73-4506, StivargaMulti-targeted RTK inhibitorApproved in Other Cancers
SunitinibSutent, Sunitinib malateVEGFR2, PDGFR-beta, c-Kit, and FLT3 kinase inhibitApproved in Other Cancers
TalazoparibMDV3800, BMN-673, Talazoparib Tosylate, TalzennaPARP inhibitorApproved in Other Cancers
TemsirolimusTorisel, CCI-779mTOR inhibitorApproved in Other Cancers
TrastuzumabHerceptin, Anti-erbB2 Monoclonal Antibody, HER2 Monoclonal AntibodyHER2 antagonistApproved in Other Cancers
VemurafenibRO5185426, PLX4032, ZelborafBRAF kinase inhibitorApproved in Other Cancers
NCT02873962IIPartially platinum sensitive or resistant ovarian cancer (for combo w/ rucaparib patients have to be BRCA WT and have no prior PARP inhibitor)A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal CancerMAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
NivolumabBMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, OpdivoBlocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
RucaparibRubraca, CO-338, PF 01367338, AG-014699PARP inhibitorApproved in Ovarian Cancer
NCT04123366IIAdvanced BRCA WT solid tumors with mutations in homologous repair (HRR) genes (i.e. BRIP1, PALB2) or HRD+ patients, no prior PARP inhibitor or checkpoint inhibitorA Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced CancerAL, AZ, CA, CO, FL, GA, KY, NJ, NY, OH, OK, TX, UT, VA, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
PembrolizumabKeytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475Blocks PD-L1/2 inhibition of T cellsApproved in Other Cancers
NCT03842228IbAdvanced solid tumors with alterations in ARID1A, ATM, ATRX, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK1, CHEK2, FANCA, FANCL, MRE11A, MSH2, PALB2, PARP1, PIK3CA (E542, E545 or H1047), POLD1, PP2R2A, PTEN, RAD51B, RAD51C, RAD51D, RAD54L or XRCC2 (in expansion)A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid TumorsCO, MA, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CopanlisibBAY 80-6946, PI3K inhibitor BAY 80-6946pan-PI3K inhibitorApproved in Other Cancers
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT02484404I/IIRecurrent ovarian cancerPhase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal CancersMDView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CediranibAZD2171, Cediranib maleate, RecentinVEGFR1-3 kinase inhibitorClinical Trials
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
NCT02953457I/IIRecurrent, persistent or refractory ovarian cancer with BRCA1/2 MUT or dMMR, HRR gene alterations or LOH high scoreA Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 MutationNYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DurvalumabAnti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, ImfinziBlocks PD-L1 inhibition of T cellsApproved in Other Cancers
OlaparibAZD2281, LynparzaPARP inhibitorApproved in Ovarian Cancer
Tremelimumabanti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, TicilimumabBlocks CTLA-4 inhibition of T cellsClinical Trials
NCT04673448IRecurrent BRCA MUT ovarian cancerPhase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary CancerWAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
DostarlimabANB011, anti-PD-1 monoclonal antibody TSR-042, TSR-042Blocks PD-L1/2 inhibition of T cellsClinical Trials
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer

If you have any questions or would like help with your search, please call us at: 858-264-5124 or email us at patientsupport@clearityfoundation.org.